The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 29 April 2026•Updated 29 April 2026•

1 min read

Regeneron Shares Slide 6.2% Despite Q1 Earnings Beat and $3 Billion Buyback Plan

Key Facts

1Regeneron reported Q1 revenue of $3.605 billion, a 19% year-over-year increase.

2Adjusted earnings per share reached $9.47, surpassing Wall Street estimates of $8.94.

about 1 month ago

Version History

Version 2about 1 month ago

What changed: Updated stock decline to 6.2%, added quarterly dividend details including payment and record dates, and specified U.S. Eylea sales weakness.

Version 1about 1 month ago

What changed: Updated the story to identify Dupixent and Eylea HD as growth drivers, while noting the plunge in original Eylea sales and rising competition as reasons for the stock decline.

Regeneron Pharmaceuticals shares extended their decline to 6.2% despite reporting first-quarter revenue of $3.605 billion, a 19% year-over-year increase. The downward pressure intensified as investors focused on declining U.S. sales of its Eylea product, overshadowing an adjusted earnings beat of $9.47 per share against the $8.94 consensus. In addition to a $3 billion share buyback authorization, the company declared a quarterly dividend of $0.94 per share. This dividend is scheduled for payment on June 4th to shareholders of record as of May 20th. Despite these capital return initiatives, the market remains wary of intensifying competition in the biotech sector. The stock's performance suggests that concerns over domestic market share erosion are currently outweighing positive financial metrics.